

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-18. (Canceled)

19. (Currently Amended) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, and wherein said irritant agent is an active agent in said composition and is selected from the group consisting of alpha-keto acids, beta-keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents;

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect; and

a cosmetically, dermatologically or pharmaceutically acceptable medium therefor ~~wherein the agent which provides the irritant side effect is selected from the group consisting of alpha-keto acids, beta-keto acids, retinoids, anthralins,~~

~~anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.~~

20. (Previously Presented) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include an interleukin-1 antagonist or a TNF-alpha antagonist, and wherein said irritant agent is an active agent in said composition;

an amount of at least one interleukin-1 antagonist and at least one TNF-alpha antagonist, sufficient to eliminate or alleviate said irritant side-effect; and

a cosmetically, dermatologically or pharmaceutically acceptable medium therefor.

21-22. (Canceled)

23. (Previously Presented) The composition of Claim 19, further comprising at least one histamine antagonist.

24. (Previously Presented) The composition of Claim 23, wherein the histamine antagonist is a heterocycle or a nitrogen compound having at least one benzene ring.

25. (Currently Amended) The composition of Claim 19, wherein the amount of the ~~compound~~ antagonist ranges from about 0.000001 to 5% by weight relative to the total weight of the composition.

26. (Currently Amended) The composition of Claim 19, wherein the amount of the ~~compound~~ antagonist ranges from about 0.0001 to 0.1% by weight relative to the total weight of the composition.

27. (Previously Presented) The composition of Claim 19, wherein the cosmetically, pharmaceutically, or dermatologically acceptable medium comprises an aqueous, oil or aqueous alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a microemulsion, an aqueous gel, an anhydrous gel, a serum, or a dispersion of vesicles, microcapsules or microparticles.

28. (Previously Presented) The composition of Claim 19, further comprising at least one active agent selected from the group consisting of anti-bacterial, antiparasitic, antifungal, anti-inflammatory, antipruriginous, anesthetic,

antiviral, keratolytic, free-radical scavenging, antiseborrheic, antidandruff and anti-acne agents and/or agents which modulate the differentiation and/or the proliferation and/or the pigmentation of skin.

29. (Previously Presented) The composition of Claim 28, wherein the active agent is selected from the group consisting of lidocaine hydrochloride, antiparasitic agents and non-steroidal anti-inflammatory agents.

30. (Previously Presented) The composition of Claim 20, wherein the agent which produces an irritant side-effect is selected from the group consisting of alpha-hydroxy acids, beta-hydroxy acids, alpha-keto acids, beta-keto acids, retinoids, anthralins, anthranoids, peroxides, minoxidil, lithium salts, antimetabolites, vitamin D and depigmentation agents.

31. (Previously Presented) The composition of Claim 20, further comprising at least one histamine antagonist.

32. (Previously Presented) The composition of Claim 31, wherein the histamine antagonist is a heterocycle or a nitrogen compound having at least one benzene ring.

33. (Currently Amended) The composition of Claim 20, wherein the amount of the ~~compound~~ antagonist ranges from about 0.000001 to 5% by weight relative to the total weight of the composition.

34. (Currently Amended) The composition of Claim 20, wherein the amount of the ~~compound~~ antagonist ranges from about 0.0001 to 0.1% by weight relative to the total weight of the composition.

35. (Previously Presented) The composition of Claim 20, wherein the cosmetically, pharmaceutically, or dermatologically acceptable medium comprises an aqueous, oil or aqueous alcoholic solution, a water-in-oil emulsion, an oil-in-water emulsion, a microemulsion, an aqueous gel, an anhydrous gel, a serum, or a dispersion of vesicles, microcapsules or microparticles.

36. (Previously Presented) The composition of Claim 20, further comprising at least one active agent selected from the group consisting of anti-bacterial, antiparasitic, antifungal, anti-inflammatory, antipruriginous, anesthetic, antiviral, keratolytic, free-radical scavenging, antiseborrheic, antidandruff and anti-acne agents and/or agents which modulate the differentiation and/or the proliferation and/or the pigmentation of skin.

37. (Previously Presented) The composition of Claim 36, wherein the active agent is selected from the group consisting of lidocaine hydrochloride, antiparasitic agents and non-steroidal anti-inflammatory agents.

38. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, wherein said irritant agent is an active agent in said composition and is an alpha-keto acid, and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect.

39. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, wherein said irritant agent is an active agent in said composition and is a beta-keto acid, and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect.

40. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, wherein said irritant agent is an active agent in said composition and is a retinoid, and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect.

41. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, wherein said irritant agent is an active agent in said composition and is an anthralin, and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect.

42. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, wherein said irritant agent is an active agent in said composition and is an anthranoid, and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect.

43. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, wherein said irritant agent is an active agent in said composition and is a peroxide, and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect.

44. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist,

wherein said irritant agent is an active agent in said composition and is a minoxidil,
and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or
alleviate said irritant side-effect.

45. (New) A composition suitable for pharmaceutical, cosmetic or
dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a
user when utilized in a composition that does not include a TNF-alpha antagonist,
wherein said irritant agent is an active agent in said composition and is a lithium salt,
and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or
alleviate said irritant side-effect.

46. (New) A composition suitable for pharmaceutical, cosmetic or
dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a
user when utilized in a composition that does not include a TNF-alpha antagonist,
wherein said irritant agent is an active agent in said composition and is an
antimetabolite, and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect.

47. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, wherein said irritant agent is an active agent in said composition and is a vitamin D, and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect.

48. (New) A composition suitable for pharmaceutical, cosmetic or dermatological usage, said composition comprising:

an amount of at least one agent sufficient to elicit an irritant side-effect to a user when utilized in a composition that does not include a TNF-alpha antagonist, wherein said irritant agent is an active agent in said composition and is a dipigmentation agent, and

an amount of at least one TNF-alpha antagonist sufficient to eliminate or alleviate said irritant side-effect.